Stifel raised the firm’s price target on Tandem Diabetes (TNDM) to $22 from $20 and keeps a Hold rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $22 from $17 at UBS
- Tandem Diabetes upgraded to Neutral from Underperform at BofA
- Tandem Diabetes Care: Solid Q4 Beat Offset by PayGo Transition Uncertainty and Competitive Headwinds Supporting Hold Rating
- Tandem Diabetes price target raised to $21 from $14 at Piper Sandler
- Tandem Diabetes reports Q4 EPS (1c), consensus (9c)